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The current study, while controlled using anatomic inclu-
sion criteria, is not randomized and therefore subject to se-
lection, measurement, and attribution biases. Small sample
sizes, although similar to those of the multicenter pivotal
FDA studies for these stent grafts, further limit the overall
generalizability of the results and our ability to perform
complex risk adjustment. Further, this study is from a single
center highly experienced in this procedure, andmulticenter
data would bemore generalizable. Our use of all-cause mor-
tality instead of aorta-related mortality was due to the lon-
gitudinal retrospective nature of the study. As such, we did
not have detailed specific information about the exact cause
of death in some patients to delineate aortic deaths from
other causes. We propose that the all-cause mortality out-
come we used in this study is the most stringent and appro-
priate for aortic patients inasmuch as sudden death is
a frequent end point from aortic rupture and is not subject
to attribution biases.SUMMARY
Among the patients in this study, TEVAR was both safe
and effective in the short and long term to treat thoracic aor-
tic aneurysms and offered similar survival to open therapies.
TEVAR patients did require repeat interventions more fre-
quently, although the vast majority of these are performed
by an endovascular approach. Aneurysm dimensions appear
to decrease maximally in the first year and remain stable
from that point onward. Further follow-up of these patients
is planned and larger multicentric studies will provide fur-
ther confirmation of these findings.References
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Dr John S. Ikonomidis (Charleston, SC). I have no relation-
ships to disclose that are relevant to this discussion. Nimesh, I en-
joyed your presentation very much. We clearly need more data
with regard to long-term outcomes in these patients.
I would like to raise a few issues related to your patient groups.
First, with the control open group, I am a little puzzled by your
choice to include 6 patients who had hypothermic circulatory ar-
rest. Why did you choose to enter those patients into this analysis
when, clearly, circulatory arrest is not used in the stent graft group,
and we know frommany studies that the use of circulatory arrest in
aortic surgery, especially longer times, is itself a predictor of neu-
rologic outcome and even mortality? The second part of that ques-
tion is, what happens to the control group if you eliminate those 6
patients?
Dr Desai. Thank you for the question. Our inclusion was based
on defined anatomic substrates. If a patient had an adequate zone 2
landing zone, he or she was considered appropriate to include in
the study. Not all patients with zone 2 landing zones cannot neces-
sarily undergo crossclamping. In this case, when the operative re-
ports were reviewed, the reasons for not clamping the aorta in that
region were aortic calcification or mobile atheroma. By compari-
son, the TEVAR IDE studies, particularly the VALOR trial (Vascu-
lar Talent Thoracic Stent Graft System for the Treatment of
Thoracic Aortic Aneurysms) for the Talent device, 40% of the pa-
tients in that group had bare metal going into zone 2 or even zone 1.
These are patients who can be treated with TEVAR, but if the op-
erations are done open they may require circulatory arrest. Theyrdiovascular Surgery c Volume 144, Number 3 609
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patients who could not be treated with TEVAR.
To answer your other question about what happens if we remove
these patients from the group:We had 1 mortality in that group and
1 stroke. The numbers are too small to really parse out those kinds
of details, and the overall objective of the study was to look at the
long-term not short-term outcomes; however, they would make the
open controls seem slightly better in the perioperative period. I be-
lieve it is more fair to go by anatomy as we did in this article, be-
cause these are people in whom we could have used a stent.
Dr Ikonomidis. While I understand that the main purpose of
this study was to assess long-term outcome, nevertheless I am in-
terested in some of the short-term information on these patients.
For example, I noticed that you had 38 patients in the TEVAR
group that had so-called A anatomy. From the diagram that you
showed, it looks as though aneurysms in this group originate
very close to the left subclavian to the point that one would pre-
sume that those patients had their left subclavian covered as part
of their procedure. Is that correct?
Dr Desai.As this was so early in our experience and these were
trial patients, we did not challenge into the arch with the TEVAR
graft as much as we would today. Many were very isolated aneu-
rysms in the proximal thoracic aorta and had a reasonable landing
zone between the aneurysm and the takeoff of the subclavian. We
may have flared into the left subclavian or put bare metal into it but
not actually covered it.
There were only 4 patients who had unplanned, that is, no pre-
operative left carotid–subclavian bypass, coverage of the left sub-
clavian, and we did not have any neurologic sequelae or arm
ischemia in those patients.
Dr Ikonomidis. What about cerebrospinal fluid drains? I no-
ticed that in the open group about 80% of patients got cerebrospi-
nal fluid drains in contrast to the TEVAR group, in which 40% got
drains. How did your neurologic complication rates distribute be-
tween those groups? Do you think that you could modify your re-
sults in the TEVAR group by more aggressive use of cerebrospinal
fluid drains? Has your strategy changed?
Dr Desai.Our strategy has not changed. The TEVAR group had
less type C coverage, so in general there was less aorta covered and
fewer intercostals disrupted. This explains most of the difference
in the rate of placement of drains. There are other factors on which
I did not elaborate here, including previous ascending aortic aneu-
rysm repair, which influence our use of drains as well. Again, we
are only looking at 4 or 5 incidents of paralysis within the whole
group, including both cohorts. It is impossible to parse out those
details.
Our protocol is that we place a drain for type C coverage and
any other previous aortic intervention in the abdominal aorta.
Dr Ikonomidis. The last issue I wanted to bring up was the ilio-
femoral arterial access complication rate. Almost 1 in 5 patients in
the TEVAR group had some sort of iliofemoral arterial access
complication. I presume all of these were not ‘‘femoral artery or
iliac artery on a stick’’ type complications. Nevertheless, it seems
to me that this rate is a bit high. Was this part of a learning curve in
the way you evaluated your patients? Did you see these complica-
tions evenly distributed over the time period? Have you modified
the way you assess your patients preoperatively in terms of your
strategy for TEVAR as a result of this?610 The Journal of Thoracic and Cardiovascular SurgDr Desai. We have definitely become more liberal with retro-
peritoneal access and also have more devices to choose from,
some of which have smaller profiles and are more flexible. There
is definitely a learning curve component. When we presented our
larger series of 500 TEVARs at the Western Thoracic in 2009,
we showed that the incidence of access complications between
the first 250 stent grafts we did and the second had been cut
in half dramatically, and they have become extremely uncom-
mon with the preoperative planning and our approach to access
in the current era. Similarly, actually, postoperative or perioper-
ative spinal ischemia in our TEVAR patients has virtually disap-
peared as an entity, and it goes beyond just putting in a drain but
also hemodynamic management approaches that we have
adopted.
Dr D. Craig Miller (Stanford, Calif). I am looking around for
Alberto Pochettino, Joe Bavaria, or Wilson Szeto, because I am
not sure it is fair to ask Nimesh some pretty tough questions. I
am afraid you will feel like John Ikonomidis just softening
you up.
You have a problem with small numbers of patients and a rela-
tively small number of adverse events in both groups, as you al-
ready have admitted; therefore, how can you really draw any
broad inferences? You also did not take full statistical advantage
of this retroelective analysis, despite matching for the patients’
anatomy. Wouldn’t this be a beautiful place to use propensity
score analysis to neutralize for the effects of confounding inde-
pendent variables? You will unbalance the numbers, but at least
you are going to have a more apples-to-apples comparison. I do
not think our standard level of clinical research reporting today
can allow retrospective comparative observations to be presented
without adjusting as much as possible for known confounders.
However, the numbers are small and may not be sufficient to gen-
erate a stable propensity model. We really need a rigorous multi-
center collaborative approach with larger patient numbers to
answer the important questions you are asking. Admittedly, we
all are guilty of cluttering the literature with our own relatively
small single-center reports, but we must figure out ways to do
better.
Second, I amafraid your conclusion slide should be redone.Your
data do not substantiate the conclusion about less morbidity with
TEVAR. The only odds ratio that was significant was the interac-
tion for women in the open group. All of the other odds ratios
crossed 1.0. How can you really conclude there is less morbidity
with TEVAR?
Dr Desai. Just to answer your first question about multivariate
adjustment, when we ran propensity matching, we encountered is-
sues with data loss.
Dr Miller. There weren’t enough comparable patients?
Dr Desai. There was a paucity of matched pairs. The Cox pro-
portional hazard model that I presented provides a similar risk ad-
justment, although not as visually elegant or easy to understand as
propensity matching. It is full multivariate risk with similar fidelity
to propensity adjustment.
In terms of morbidity issues, we showed in the perioperative pe-
riod that prolonged ventilation was statistically significantly more
common in open patients. The other complications also tended to
be higher in open patients, and in a larger sample that difference
may or may not be significant.ery c September 2012
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is likely to be significant in a larger series. I think you would be
hard pressed to show major differences, even in a fairly large trial,
in terms of mortality, spinal complications, or stroke with contem-
porary management of the open and TEVAR cases.
DrMiller.We have to go back and look at those odds ratios and
see which ones cross 1.0. This may look like the EVEREST-II trial
(Endovascular Valve Edge-to-Repair Study): It looks great on the
surface, but digging deeper reveals it is only due to differences in
transfusions and ventilator time. My point is that I am concerned
you are overstating your conclusions.
You mentioned on that slide that historical paraparesis/paraple-
gia rates after open surgical graft replacement were all 2% to 8%. It
should be noted that the first report on the list from Joe Coselli’s
group had a rate of 0.8%.
Dr Desai. That was 0.8% for permanent total flaccid paralysis,
and it was another 5.7% for permanent paraparesis, which has
a pretty broad definition.
Dr Miller. Fair enough. It also is an adverse event defined sub-
jectively and differently around the world. My current hobbyhorse
is voicing concern that the entire thoracic field is being ‘‘dumbed
down’’ as the TEVAR era (which we at Stanford started 19 years
ago in 1992) evolves, in no small part owing to studies similar to
yours in which the rule of ‘‘noninferiority’’ is taken as gospel.
Even centers that used to know how to do open thoracic aortic sur-
gery with reasonable results are losing those skills over time. We
need to remind ourselves that the jury is still out regarding long-
term durability, reintervention rates, and survival after TEVAR
compared with after open graft replacement.
DrMarcR.Moon (St Louis,Mo).Didyourgrowth slide show that
some of the aneurysmswent from 4 cm up to 7 or 8 cm on follow-up?
Dr Desai. In a couple of cases, yes.
Dr Moon. What was going on there?
Dr Desai. A couple of those were converted to open. One of the
lessons inourearly experiencewithTEVARis, ifyouhaveaproximal
type I endoleak, it can evoke an unstable situation. Those aneurysms
often will grow very quickly and possibly more quickly than if you
had left them alone. You are mandated to reintervene either by put-
ting a stent in and getting a proximal seal or reoperating on that pa-
tient in an open fashion. There is definitely a group of patients whose
aortas will dilate out very quickly if you do not get a proximal seal.The Journal of Thoracic and CaDr Moon. Were you replacing 4-cm aortas? What was the
cutoff?
Dr Desai. Smaller sizes were seen in saccular aneurysm with
rapid expansion.
Dr Pochettino. I would like to respond to Dr Miller’s comment
Inasmuch as I did most of the open procedures. I was actually sur-
prised at how good the outcomes of open thoracic replacement
were. That occurred despite the fact that the majority of the
open operations were done via thoracotomy when the patients be-
came unstable. The reality of the trial was that the stent grafts were
not readily available, and a minimum of 6 to 8 weeks was neces-
sary to design the endovascular repair and obtain the needed de-
vices from the manufacturers. If the patients were stable for 6 to
8 weeks for the stent to be manufactured and shipped over, they
would undergo endovascular therapy. There was an intrinsic bias
of most of the patients having open surgery being relatively unsta-
ble with some of them being on the verge of aortic rupture. Despite
that, the outcomes of open thoracic replacement were quite good.
Nearly all of the open repair patients wewould treat today with en-
dovascular techniques.
In principle, I agree with the need for a large multi-institutional
randomized study of open versus endovascular treatment of tho-
racic aortic aneurysm. However, with present technology, in to-
day’s world, it has become impossible to randomize between
open and stent grafts. No patient would be willing to enter that
study. A priori, I do not have the insight to know what is best for
them, although deep down I have some opinions I could share
with the patients. The opportunity to perform that large random-
ized study has escaped us and I do not think it is ever going to
be made in today’s world.
Dr Desai. If I can summarize, there certainly is a feeling by
some in the literature that putting a stent graft in an aorta does
not change the natural history of the aneurysmal disease, and
that EVARs or TEVARs do not prolong people’s lives the way
that open surgery does. What we tried to show in this article was
that whether you had an open operation or a TEVAR, within the
limitations of the data we have discussed, your survival was sim-
ilar. We do not have a true control group of patients who did not
get operated on, but being operated on in an open fashion or having
a TEVAR led to the same outcome, and the patient can choose
which procedure he or she wants.rdiovascular Surgery c Volume 144, Number 3 611
